Two Baxter Saline Lots Reached New York Healthcare Providers. Check These Exact Identifiers.

DRUG RECALL — HEALTHCARE, MENTAL HEALTH & AGING

Two Baxter saline lots reached New York healthcare providers. Check these exact identifiers.

This is a provider-facing supply recall—not a warning about every bag of saline. Baxter says the affected 500 mL VIAFLEX product was distributed to healthcare providers and distributors in New York and 13 other states. No Rockland facility, distributor or patient has been confirmed in the public announcement.

The Rockland Edit recall guide listing Baxter 0.9% Sodium Chloride Injection in a 500 mL VIAFLEX container, product code 2B1323Q, NDC 0338-0049-03, lots Y495523 and Y495523A, and expiration October 31, 2027 — Identification graphic by The Rockland Edit, based on the FDA-posted Baxter announcement. It is an original editorial card—not a product photograph, package label or medical instruction.

Match every detail

Product: Baxter 0.9% Sodium Chloride Injection, USP.
Container: 500 mL VIAFLEX Plastic Container; 24 per case.
Product code and NDC: 2B1323Q and 0338-0049-03.
Lots: Y495523 and Y495523A.
Expiration: October 31, 2027.

This recall is directed to facilities

Baxter says customers should immediately discontinue use of affected units and return them according to their facility’s process. The company says it is contacting customers by email with identification and return instructions. That action applies only when the product, container, product code, NDC, lot and expiration match.

If you are a patient or caregiver and see one of these identifiers in a care setting or record, do not interrupt treatment or handle the product independently. Ask the treating facility or healthcare provider to verify the supply. Anyone who experienced a problem that may be related to the product should contact a physician or healthcare provider.

Why Baxter recalled the lots

The FDA-posted company announcement says potential particulate matter identified as fiberglass was found in the solution. Baxter’s risk statement says intravenous administration of affected solution may cause blocked or clotted blood vessels, a life-threatening blood clot in the lungs, permanent organ damage or death. It also lists vein irritation, inflammation, aggravated infection and allergic reactions. Those risks are company-attributed; the announcement does not say every recalled unit contains particulate matter.

Baxter reported no related adverse events as of August 25, 2026. The public announcement does not provide a recall classification, and The Rockland Edit is not inferring one.

What New York distribution does—and does not—confirm

The affected product was distributed from July 31 through August 3 to healthcare providers and distributors in New York and 13 other states. The announcement does not name a Rockland hospital, dialysis center, infusion provider, distributor or patient. New York distribution is confirmed; Rockland receipt is not.

Questions and adverse-event reports

Baxter lists the Healthcare Center for Service at 888-229-0001, Monday through Friday from 7 a.m. to 6 p.m. Central Time. Patients and healthcare professionals may also report adverse reactions or product-quality problems through the FDA’s MedWatch program ↗.

The useful version is narrow: match the 500 mL VIAFLEX container, product code 2B1323Q, NDC 0338-0049-03, lot Y495523 or Y495523A, and the October 31, 2027 expiration. Facilities should discontinue and return matches through their process; patients should ask their provider to verify the supply.

Primary source: FDA-posted Baxter company announcement ↗, dated August 25 and published August 26, 2026. Product identifiers, distribution, instructions, contact information and adverse-event statement rechecked August 31, 2026, at 3:24 a.m. EDT. FDA posts company announcements as a public service and does not endorse the product or company. This service guide is not individualized medical advice.